What is less comprehended is why drug companies spend billions for research o-n off-label uses for their services and products - when the drug was submitted for approval uses that were never cleared with the FDA.

Off-label use allows drug organizations to get 'through the back door' what they might never, and I am talking about never, break free with by going right to the FDA for approval for a new use of a solution - what's known today as an off-label use.

You would hope that researchers wouldn't corrupt the commercial experimentation of a new, or off-label, utilization of a drug to treat kiddies by covering up their consulting costs from Big Pharma. But that's what happened.

Harvard Drug Research Fraud and Cover-up: How Off-Label Profiteering Works

Drug business money corrupts and influences re-search. For another way of interpreting this, people might claim to peep at: Zofran Lawsuit Plaintiffs Allege Drug Was Marketed “Off-Label" For Increased Profit. Dig up further on a related website - Click here: Zofran Lawsuit Plaintiffs Allege Drug Was Marketed “Off-Label" For Increased Profit. That's confirmed.

What is less comprehended is why drug companies spend billions for re-search on off-label uses for their products and services - uses which were never cleared using the FDA when the drug was submitted for approval.

Off-label use allows drug organizations to get 'through the back door' what they are able to never, and I mean never, escape with by going right to the FDA for approval for a new use of the product - what's known today being an off-label use.

You'd hope that scientists would not corrupt the industrial testing of a new, or off-label, utilization of a drug to treat young ones by covering up their consulting fees from Big Pharma. But that is what happened.

More essential than what happened is excatly why it happened and at the base of this is a bad mistake the U.S. has produced in enabling the exploitation of off-label use.

The devil is in the facts, therefore here is the story because it has unfolded.

Leading Harvard professors studying off-label uses, the gold-mine of the drug industry, have broken National Institute of Health reporting requirements when more than $10,000 has been received from a subject organization, according to the New York Times, 'Researchers Neglect to Reveal Drug Pay' June 8, 2008. http://www.nytimes.com/2008/06/08/us/08conflict.html?em&ex=1213070400&en=9971013dfd33290a&ei=508720say20are%20sorry&st=cse isn't enough.

If Harvard doesn't fire them, it will be complicit in the cover-up.

Put them off campus. Ring the bell loud and clear that no matter how renown or stellar, if you don't play by the principles, you can not play at all. And THEY should be forever banned by the NIH from receiving grants.

Don't get rid of the child with the bath water. Once appropriate punishment is served, give these researchers a chance to develop their tarnished reputations. Allow them to conduct research under the direction of a responsible officer who knows that 'veritas,' means truth, accuracy, integrity, and uprightness and that it's more than only a slogan.

Onward.

Richard Alexander

http://www.alexanderinjury.com. My father discovered Zofran Lawsuit Plaintiffs Allege Drug Was Marketed “Off-Label" For Increased Profit by searching the Houston Watchman.